Mangoceuticals Announces $2.5M Private Placement of MangoRx IP

What Happened

• Mangoceuticals, Inc. (MGRX) reported in an 8‑K (filed Oct 1, 2026) that its wholly‑owned subsidiary, MangoRx IP Holdings, LLC, which holds the patent portfolio for the company’s antiviral technology MGX‑0024, entered into subscription agreements with two accredited investors to sell a combined 25% interest in MangoRx IP for aggregate consideration of $2,500,000.
• One investor agreed to buy 12.5% for $1,250,000 (payable $500,000 at signing in cash or Tether (USDT) and $750,000 no later than 60 days after closing); the other agreed to buy 12.5% for $1,250,000 payable at the initial closing. As of the filing date the company has received $1,750,000 and issued the investors 18.9% of MangoRx IP (17.5% on a post‑transaction basis); the investors’ ownership will increase to 25% upon final closing. The subscription agreements include customary representations and warranties and are attached as Exhibits 10.1 and 10.2. A company press release about the investments was issued Oct 1, 2026.

Key Details

• Total subscription commitments: $2,500,000 for 25% of MangoRx IP (two investors, each 12.5%).
• Cash received to date: $1,750,000; payment terms include optional payment in Tether (USDT).
• Current issued interest to investors: 18.9% (17.5% on a post‑transaction basis); will reach 25% after final closing.
• MangoRx IP is a wholly‑owned Mangoceuticals subsidiary holding the MGX‑0024 patent portfolio.

Why It Matters

• The transaction brings near‑term cash to Mangoceuticals through the sale of a minority stake in the subsidiary that holds its antiviral patents.
• Investors taking an ownership stake in MangoRx IP means the company will no longer hold 100% of that patent portfolio if the final closing completes (investors would hold 25%).
• Retail investors should note the material agreement was disclosed via Form 8‑K and press release; subscription agreements are filed as exhibits for further details on terms.